Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer – A population-based study
Susan J. Jordan(The University of Queensland), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Anna DeFazio(The University of Sydney), David Wyld(QIMR Berghofer Medical Research Institute), Suzanne O’Brien(King's College London), Michael Quinn(University of Rochester), Geraldine Goss, Christopher Steer(Albury Wodonga Health), Andreas Obermair(Royal Brisbane and Women's Hospital), Jane E. Francis(Royal Geographical Society), Michael Friedländer(Prince of Wales Hospital)
Cited by 36
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k